For example, the evidence from RWE supports the findings from CVOTs showing a reduction in HHF with SGLT2 inhibitors, which suggests that the reduction in HHF demonstrated in CVOTs may be observed in T2D patients across a broad continuum of CVD in routine clinical practice. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.